Q BioMed Inc.
366 Madison Avenue, 3rd Floor
New York, NY 10017
Telephone: +1 646 889 2226
www.qbiomed.com

Company Overview

Accelerating Biomedical Technologies from Incubation to Monetization

Q BioMed (QBIO) aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company's FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019. Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron. The Company's robust clinical pipeline is expected to produce growing revenues for the Company and value infection points for investors.

Equity Overview *(as of January 22, 2019)*

Ticker: QBIO

Stock Price: $2.23

Shares Outstanding: 14.3 M

Market Cap: $31.9 Million

Avg. Trading Volume (90 day): 49,287

Inside Ownership: 26.5%

Commercialized Product

METASTRON™

$25 M - $50 M Annual Revenue Potential

- ✓ FDA approved to treat bone pain from cancer metastases
- ✓ Medicare reimbursed in U.S.
- ✓ U.S. Sales expected in 2019
- ✓ Approved in 22 countries

$250 M - $500 M Annual Revenue Potential

- ✓ Potential to treat bone cancer
- ✓ Increased survival by 9 months
- ✓ Phase IV clinical trials planned to support label extension and cancer survival benefit
- ✓ Competing product generates $800 M/year

Disclaimer: Except for historical information contained herein, the statements in this fact sheet are "forward looking" within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements and their implications are based on the current expectations of our management only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. A fuller discussion of Q BioMed Inc.'s risks and uncertainties are described in the Company's filings with the U.S. Securities and Exchange Commission, which should be reviewed in conjunction with this overview.

Investment Highlights

Commercializing FDA Approved Metastron for Non-Opioid Pain Relief

Metastron is an FDA approved, non-opioid drug that relieves the severe pain associated with cancer that has metastasized to bones. Due to the opioid crisis, doctors are looking for alternatives to treat cancer-associated pain. The Company purchased the asset from GE Healthcare because Q BioMed recognizes a huge potential for Metastron in other cancer indications. Q BioMed expects to generate revenues from the current FDA approved indication of Metastron in 2019 and expects revenues to reach $25 to $50 million annually in the next 3 years. Based on data published in The Lancet, Q BioMed is planning a Phase IV clinical trial for Metastron to support label extension and survival benefit for the treatment of metastatic bone cancer. This new expanded indication has the potential to general $250 to $500 million in revenues annually.

QBM-001 for Pediatric Non-Verbal Disorder in Dire Need of Treatment

18,000 children in the U.S. and 40,000 worldwide with a specific Autism Spectrum Disorder (ASD) are minimally verbal or non-verbal as toddlers. Left untreated, these children will have to rely on assisted living for the rest of their lives, leading to emotional costs for the family as well as an estimated $10 million per person over a lifetime and an annual cost to the healthcare system of $200 billion. Q BioMed plans to submit a Pre-IND and Orphan Drug filing with the FDA in the coming quarter with an aim to initiate a clinical trial in Q3 2019.

Uttroside-B is 10X More Potent Against Liver Cancer

Uttroside-B is up to 10 times more potent against liver cancer cells than Sorafenib (pre-clinical data), the only FDA approved drug for first line treatment of liver cancer. 700,000 people per year are diagnosed with liver cancer, with a very poor 5 year survival rate of 18% due to lack of effective treatments. Q BioMed plans to file an IND with the FDA in 2019 to start a clinical trial in this indication.

Man-01 to Treat Glaucoma with Addressable Market of 60 M People

Man-01 has shown to normalize Intraocular Eye Pressure (IOP) which is present in glaucoma patients. Q BioMed expects to submit an IND to the FDA in 2019. The Mannin platform has several potential drugs for treating vascular disease.

Robust Pipeline